Another 3D printing company has jumped into the public sector! Wait. That’s not right. Another 3D printing company has gone public! This time, it’s another medical tech company. But ConforMIS Inc. (NASDAQ: CFMS) isn’t into bioprinting. Instead, the firm, which launched its IPO of $9 million shares at $15 per share, creates custom joint implants, specifically knee implants, using their own proprietary technology.

On top of the partial or complete knee implants themselves, the company also produces custom surgical instruments, or iJigs, for installing the implants that are disposed of after the procedure. This allows for a reduction in both the clutter in the operating room and, thus, more importantly, the time a knee surgery takes. To me, it’s this sort of small detail that indicates ConforMIS is actually make important progress in the medical field.
The company went public yesterday, July 1, and closed the day at $19.25 a share, while, today, the stock is spiking up to the $22 level. The joint bookrunners for the offering were JPMorgan and Deutsche Bank, with Wells Fargo Securities, Canaccord Genuity and Oppenheimer all acting as co-managers. And the underwriters have a 30-day option to buy up 1.35 million more shares. ConforMIS states that the global market for joint replacements is $15 billion and writes their 2014 revenue to be $48.2 million and $14.7 million for Q1-2015.
If you’re one of those people out there investing in every and any 3D printing stock, then you might want to look into this company. And, if you’re interested in medicine and 3D printing stocks, in general, Materialise is another to look at, as they’ve been involved in medical 3D printing for some time. If, on the other hand, you believe thatthe stock market is in for an imminent collapse, hide your money under your mattress, where it will appreciate in sentimental value.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น